-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Dicerna Pharmaceuticals announced today that the company's research RNAi therapy DCR-AUD has completed the first batch of subjects in a phase 1 clinical trial for the treatment of patients with alcohol use disorder (AUD)
.
Alcohol use disorder is a chronic disease characterized by the inability to stop or control alcohol use despite social, occupational, or health consequences
.
Symptoms may include compulsive drinking, loss of control over drinking, and negative emotions when not drinking
DCR-AUD is a GalXC RNAi drug candidate developed by Dicerna, which aims to silence the expression of mRNA encoding acetaldehyde dehydrogenase 2 (ALDH2) in the liver
.
In non-clinical studies, DCR-AUD can permanently reduce the mRNA encoding ALDH2 in the liver
Dicerna designed DCR-AUD based on human genetic data, showing that knocking out ALDH2 mRNA in AUD individuals may provide similar physiological feedback, thereby preventing harmful levels of alcohol consumption
.
Image source: Dicerna's official website
This study will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of DCR-AUD in healthy volunteers
.
The trial will also evaluate the interaction between DCR-AUD administration and alcohol consumption
Reference materials:
[1] Dicerna Initiates Phase 1 Clinical Trial of DCR-AUD, a Novel Investigational GalXC™ RNAi Therapeutic Candidate for the Treatment of Alcohol Use Disorder.
(The original text has been deleted)
